Lyell Immunopharma
LYEL
92 hedge funds and large institutions have $404M invested in Lyell Immunopharma in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 14 closing their positions.
586% more call options, than puts
Call options by funds: $48K | Put options by funds: $7K
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.07% more ownership
Funds ownership: 2.27% → 2.34% (+0.07%)
1% less funds holding
Funds holding: 93 → 92 (-1)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
51% less capital invested
Capital invested by funds: $823M → $404M (-$419M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$16.7M |
| 2 |
Goldman Sachs
New York
|
+$4.11M |
| 3 |
BlackRock
New York
|
+$2.19M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.95M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.61M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$1.27M |
| 4 |
KHCM
Kettle Hill Capital Management
New York
|
-$1.16M |
| 5 |
Morgan Stanley
New York
|
-$974K |
LYEL Hedge Fund Activity: Q4 2022 in Review
92 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2022, worth a combined $404M — down 51% from $823M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LYEL positions and 14 closed out — a net gain of 1 holder — while 32 added to existing stakes and 18 trimmed.
The largest buyer was State Street, adding an estimated $16.7M. The largest seller was T. Rowe Price Associates, cutting an estimated $8.1M.
- 92 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2022, down from 93 in Q3 2022.
- Funds reported $404M of Lyell Immunopharma stock for Q4 2022, down 51% quarter-over-quarter.
- 15 funds opened new Lyell Immunopharma positions in Q4 2022 and 14 closed out, a net change of +1 holder.
- The largest Lyell Immunopharma buyer in Q4 2022 was State Street, an estimated $16.7M added.
- The largest Lyell Immunopharma seller in Q4 2022 was T. Rowe Price Associates, an estimated $8.1M sold.
Based on aggregated 13F filings for Q4 2022.